首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1738699

2026 年至 2032 年胃轻瘫治疗市场（按药物、疾病类型、给药途径、最终用户和地区划分）

Gastroparesis Treatment Market By Drug, Disease Type, By Route of Administration, End-Users, And Region for 2026-2032

出版日期: 2025年05月03日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

胃轻瘫治疗市场评估-2026-2032

全球糖尿病胃轻瘫治疗市场受多种因素驱动，例如与其他疾病关联风险增加、糖尿病胃轻瘫家族病史以及遗传性疾病。市场对标靶治疗的日益关注以及政府的利好政策预计将进一步刺激市场成长，从而在预测期内为市场成长提供众多机会。快速的都市化、生活方式的改变以及频繁饮酒和吸烟的日益盛行也是推动市场规模扩大的因素。此外，製造商推出的新药预计将扩大市场规模，预计2024年市场规模将超过62.1342亿美元，到2032年将达到约79.0521亿美元。

持续的资金投入旨在为当前的胃轻瘫药物治疗引入新方法的研究和开发研究预计将促进市场成长。外科手术的增加和人口老化是推动胃轻瘫治疗市场在 2026 年至 2032 年期间以 3.5% 的复合年增长率增长的关键驱动因素。

胃轻瘫治疗市场定义/概述

胃轻瘫是一种由于肌肉运动或神经功能障碍导致排放延迟，从而导致食物在胃中停留时间异常长的疾病。

胃轻瘫治疗市场包括用于管理和缓解由糖尿病、神经系统疾病、特发性疾病和其他因素引起的排放延迟症状的药物、医疗设备和治疗方法，目的是改善胃动力、减少噁心和呕吐并提高患者的生活品质。

胃电刺激设备植入腹部，用于调节胃动力并缓解胃轻瘫症状。这些电刺激设备会向胃部发送电脉衝，改善排放。胃轻瘫的治疗方法包括饮食疗法，例如少量多餐和补充流质营养。行为疗法和咨商也能有效控制症状，改善患者的整体幸福感。

胃轻瘫的治疗强调个别化治疗，并充分考虑患者的个别因素和病情严重程度。智慧型手机应用程式和穿戴式装置等数位健康技术可以帮助远端监测症状。学术界、产业界和医疗机构之间的合作有望推动创新，改善病患预后。

不断增加的研发投入将如何推动胃轻瘫治疗市场的发展？

加大研发投入，助力製药公司创新开发胃轻瘫新药、新配方和新疗法。加大研发投入，助力製药公司创新开发胃轻瘫新药、新配方和新疗法。引入创新治疗方法并丰富新药研发管线，将有助于这些製造商在竞争中脱颖而出，并在胃轻瘫治疗市场中占据更大份额。

糖尿病盛行率的不断上升意味着糖尿病胃轻瘫风险的患者群体不断增长，这为提供胃轻瘫治疗的製药公司、医疗设备製造商和医疗保健提供者创造了巨大的市场机会。

此外，糖尿病性胃轻瘫的盛行率日益上升，也推动了治疗方法的创新，例如开发新型药物、微创医疗设备以及针对胃轻瘫患者特定需求的先进治疗方法。这些技术进步正在促进胃轻瘫治疗市场的扩张和多元化。

酒精和烟草成瘾率的上升以及人口老化可能会影响胃轻瘫治疗市场，因为这会增加胃轻瘫的发病率，推动对有效治疗方法的需求，给疾病管理带来挑战，并需要注重预防和教育，以及量身定制的治疗方法。

胃轻瘫治疗的成本和功能会抑制市场吗？

胃轻瘫的先进治疗方法，例如胃电刺激设备和微创手术，通常价格不斐。这些高昂的费用使得保险不足和经济困难的患者难以获得这些治疗。因此，相当一部分患者可能无法负担这些先进疗法，从而限制了这些疗法的普及，并阻碍了市场的成长。

胃轻瘫治疗相关严重副作用的发生率不断上升，可能引发对病人安全的担忧。监管机构密切监测认证核可药的安全性。根据新出现的安全性数据，监管机构可能会施加限制和警告。大众对安全性问题的认知可能会削弱对某些药物的信心，并降低患者和医生对这些治疗方法的接受度，从而减缓市场成长。

胃轻瘫新药的核准流程漫长而复杂。製药公司必须进行大量的临床前和临床试验，以证明其产品的安全性和有效性，这可能需要数年时间并需要大量的资金投资。监管核准流程的延误或受阻可能会阻碍新治疗方法的及时上市，并减缓市场成长。

Increasing risk associated with other diseases, family history of diabetic gastroparesis, and genetic diseases are several factors propelling the global market for diabetic gastroparesis treatment. The market growth will be further stimulated by the increasing focus on targeted therapies and favorable government policies. This will lead to numerous opportunities for the growth of the market during the forecast period. Also, rapid urbanization, changing lifestyles, and an increase in the prevalence of frequent alcohol and tobacco use. Additionally, the launch of novel medications by the manufacturers is driving the market size to surpass USD 6213.42 Million in 2024 to reach a valuation of around USD 7905.21 Million by 2032.

Constant funding for R&D studies aimed at introducing new approaches to the current drug therapy for gastroparesis is anticipated to augment market growth. Increasing surgical procedures and the aging population are the main drivers propelling the gastroparesis medicine market to grow at a CAGR of 3.5% from 2026 to 2032.

Gastroparesis Treatment Market: Definition/ Overview

Gastroparesis is a medical condition causing delayed stomach emptying due to impaired muscle motility or nerve dysfunction, resulting in food remaining in the stomach for an abnormally long period.

The Gastroparesis Treatment Market includes pharmaceuticals, medical devices, and therapies for managing and alleviating symptoms of delayed gastric emptying, caused by factors like diabetes, neurological disorders, or idiopathic reasons, aiming to improve gastric motility, reducing nausea and vomiting, and enhancing patient quality of life.

Gastric electrical stimulation devices are implanted in the abdomen to modulate gastric motility and alleviate symptoms of gastroparesis. These devices deliver electrical impulses to the stomach to improve gastric emptying. Therapeutic approaches for gastroparesis may include dietary modifications, such as eating smaller, more frequent meals or consuming liquid nutritional supplements. Behavioral therapies and counseling may also be beneficial in managing symptoms and improving patients' overall well-being.

The focus is on personalized gastroparesis treatment, considering individual patient factors and disease severity. Digital health technologies, like smartphone applications and wearable devices, can help monitor symptoms remotely. Collaborative research between academia, industry, and healthcare organizations is expected to drive innovation and improve patient outcomes.

How will the Rise in R&D Investments Drive the Market of Gastroparesis Treatment?

Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. By introducing innovative therapies and maintaining a robust pipeline of novel drugs, these manufacturers can differentiate themselves from competitors and capture a larger share of the Gastroparesis Treatment Market.

The rising incidence of diabetes means a larger pool of patients at risk of developing diabetic gastroparesis. This expanding patient pool presents a substantial market opportunity for pharmaceutical companies, medical device manufacturers, and healthcare providers offering gastroparesis treatments.

Also, the growth in diabetic gastroparesis cases spurs innovation in treatment modalities, including developing novel drugs, minimally invasive medical devices, and advanced therapeutic approaches tailored to the specific needs of gastroparesis patients. These technological advancements contribute to the expansion and diversification of the Gastroparesis Treatment Market.

Rising rates of regular alcohol and tobacco consumption coupled with an aging population can influence the Gastroparesis Treatment Market by increasing the incidence of gastroparesis, driving demand for effective treatments, presenting challenges in disease management, focusing on prevention and education, and necessitating tailored treatment approaches.

Will Costs and Side Effects of Gastroparesis Treatment Restrain Its Market?

Advanced treatment modalities for gastroparesis, such as gastric electrical stimulation devices or minimally invasive surgical procedures, often come with substantial costs. These costs can make these treatments inaccessible to patients without adequate insurance coverage or financial resources. As a result, a significant portion of the patient population may be unable to afford these advanced therapies, limiting their adoption and impeding market growth.

Increasing incidence of serious side effects associated with gastroparesis drugs may raise concerns about patient safety. Regulatory agencies closely monitor the safety profile of approved medications. They may impose restrictions or warnings based on emerging safety data. Public awareness of safety issues can undermine confidence in certain drugs and dampen market growth by reducing patient and physician acceptance of these treatments.

The regulatory approval process for new gastroparesis drugs can be lengthy and complex. Pharmaceutical companies must conduct extensive preclinical and clinical trials to demonstrate the safety and efficacy of their products, which can take several years and involve significant financial investments. Delays or setbacks in the regulatory approval process can hinder the timely introduction of new treatments to the market, slowing down market growth.

Category-Wise Acumens

How will the Increasing Prevalence of Diabetic Gastroparesis Drive the Growth of the Market?

The diabetic gastroparesis segment is anticipated to hold a major share of the Gastroparesis Treatment Market. Diabetic gastroparesis (DGp) is a neuropathy disorder caused by poorly managed type 1 and type 2 diabetes, ruled out by diagnostic workups, excluding obstruction and potential gastric emptying drugs.

Increasing diabetes mellitus population worldwide enables a high demand for diabetic gastroparesis drugs. According to the IDF data published in September 2021, it is estimated that around 537 million adults will be living with diabetes in 2021. Additionally, the total number of people with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 out of 4 adults with diabetes will be living in low- and middle-income countries in 2021. Pharmaceutical companies and researchers are developing drugs for diabetic gastroparesis, driving market growth. Processa Pharmaceuticals initiated a Phase 2A trial for PCS12852, a potential gastroparesis treatment.

Government initiatives aimed at addressing the rising prevalence of diabetes and its complications can indirectly support the Gastroparesis Treatment Market. Policies focused on improving diabetes management, enhancing access to healthcare services, and promoting research and development in gastroenterology can create a conducive environment for market growth.

Incentives such as research grants, regulatory support, and public health campaigns further drive investment in diabetic gastroparesis treatment. Therefore, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus leading to segment growth.

Which Factors Enhance the Use of Prokinetic Agents in Gastroparesis Treatment?

The prokinetic agents segment dominated the market owing to the effectiveness and safety of the drugs that come into this category. Prokinetic agents are a type of medication that increases the contractions of stomach muscles, which helps to improve the overall movement of the stomach. These drugs are often prescribed to patients who are suffering from gastroparesis, a condition that causes symptoms such as nausea and vomiting and hinders digestion.

Prokinetic agents are considered a cornerstone in the treatment of gastroparesis because they address the underlying issue behind the condition. In addition to their role in treating gastroparesis, these drugs have also been studied for their efficiency and safety in critically ill patients receiving enteral nutrition. The results have shown that they are effective in reducing feeding intolerance among such patients.

Also, prokinetic agents can provide effective symptom relief in patients with gastroparesis by reducing the frequency and severity of gastrointestinal symptoms. This includes alleviating nausea, vomiting, abdominal discomfort, and postprandial fullness, which are common manifestations of delayed gastric emptying in gastroparesis patients, thus leading to segment growth.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Gastroparesis Treatment Market?

North America is expected to lead the gastroparesis medicine market due to its aging population and an increase in surgical treatments. The United States is at the forefront of the market, primarily because of its large population with diabetes, favorable reimbursement policies, and increased awareness of the ailment. In June 2022, the CDC reported that 96 million adults in the US have prediabetes, accounting for 38.0% of the adult population. The region's dominance in the industry is due to a rise in healthcare expenditure, a growing hospital population, and well-established infrastructure.

The North American region boasts of an advanced healthcare infrastructure and robust research and development initiatives that foster innovation in treatment options. The well-developed reimbursement systems and insurance coverage in the region also enhance patient access to treatment, leading to an increase in market demand.

Moreover, there is a high prevalence of gastroparesis cases in North America, which is often associated with conditions such as diabetes and post-surgical complications, thereby driving the demand for effective therapies. The growing aging population, which is prone to gastroparesis, coupled with an increasing focus on healthcare technologies, contributes to North America's dominant position in the Gastroparesis Treatment Market. As a result, it continues to lead in terms of market size and influence.

Will Rising Industrialization Enhance Adoption of Gastroparesis Treatment in Asia Pacific?

Rising urbanization and economic expansion in the Asia Pacific region drive the market for gastroparesis treatment by improving healthcare infrastructure, increasing the prevalence of chronic diseases, boosting healthcare spending, and fostering technological advancements and innovation. These factors create a conducive environment for market growth.

Economic growth plays a crucial role in fostering technological advancements and innovation in healthcare. This leads to the development of new diagnostic tools, treatment modalities, and therapeutic approaches for gastroparesis. Healthcare providers in urban areas are fortunate enough to have access to cutting-edge medical technologies and state-of-the-art treatment options. This improved access to healthcare leads to better outcomes for patients and drives market expansion.

Moreover, economic prosperity attracts investments in research and development, leading to the introduction of novel drugs and devices for gastroparesis treatment in the Asia Pacific market.

Competitive Landscape

The competitive landscape of the Gastroparesis Treatment Market is fragmented, with a mix of established players and emerging companies developing novel therapies. Major players focus on medications (prokinetics, antiemetics), while others are involved in medical devices (gastric electric stimulation) and nutritional support methods.

The organizations are focusing on. Rising research and development efforts aim to address the limitations of existing treatments and introduce new options. Some of the prominent players operating in the Gastroparesis Treatment Market include:

Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc., AbbVie Inc. (Allergan Plc), Marel, Formax, Weber, Devro, Tipper Tie, Handtmann, Middleby Corporation, GEA Group, Evoke Pharma, R. Bard, Inc., Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals.

Latest Developments

Disease Type:
Diabetic gastroparesis
Idiopathic gastroparesis
Post-surgical gastroparesis
Route Of Administration:
Intravenous
Nasal
Oral
End-Users:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region:
North America
Europe
Asia-Pacific
South America
Middle East & Africa

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Gastroparesis Treatment Market, By Drug

Prokinetic Agents
Antiemetic
Botulinum Toxin Injections
Nutritional Support

5. Gastroparesis Treatment Market, By Disease Type

Diabetic gastroparesis
Idiopathic gastroparesis
Post-surgical gastroparesis

6. Gastroparesis Treatment Market, By Route Of Administration

Intravenous
Nasal
Oral

7. Gastroparesis Treatment Market, By End-Users

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

8. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

9. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

10. Competitive Landscape

Key Players
Market Share Analysis

11. Company Profiles

Evoke Pharma
AstraZeneca
Cadila Pharmaceuticals
Neurogastrx, Inc.
AbbVie Inc. (Allergan Plc)
Marel
Formax
Weber
Devro
Tipper Tie
Handtmann
Middleby Corporation
GEA Group
Evoke Pharma
R. Bard, Inc.
Rhythm Pharmaceuticals, Inc.
Boston Scientific Corporation
Kimberly-Clark Corporation
Vanda Pharmaceuticals

12. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

13. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年胃轻瘫治疗市场（按药物、疾病类型、给药途径、最终用户和地区划分）

Gastroparesis Treatment Market By Drug, Disease Type, By Route of Administration, End-Users, And Region for 2026-2032

胃轻瘫治疗市场评估-2026-2032

不断增加的研发投入将如何推动胃轻瘫治疗市场的发展？

胃轻瘫治疗的成本和功能会抑制市场吗？

目录

第一章 引言

第二章执行摘要

第三章市场概述

第四章 胃轻瘫治疗市场（依药物）

5. 胃轻瘫治疗市场（依疾病类型）

6. 胃轻瘫治疗市场（依给药途径）

7. 胃轻瘫治疗市场（依最终用户划分）

第八章区域分析

第九章市场动态

第十章 竞争格局

第十一章 公司简介

第十二章 市场展望市场展望与机会

第十三章 附录

Gastroparesis Treatment Market Valuation - 2026-2032